Indeed survivin-ΔEx3 overexpression may counter the preferential killing of highly proliferating tumor cells by doxorubicin, thus diminishing the efficacy of chemotherapy against this potentially susceptible cellular compartment. The gene discussed is BIRC5; the disease is neoplasm.